Chuangao Wu on Muck Rack

Chuangao Wu

As seen in: Frontiers in Public Health
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chuangao

Contact Chuangao, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma

|
By Zhuqing Dong, Xiulan Chen, Chuangao Wu, Tingfang Wei, Xingfa Ye
| Frontiers in Public Health
Abstract Background: The HEPATORCH trial demonstrated that toripalimab plus bevacizumab (TOR-BEV) offers superior survival outcomes for patients with advanced hepatocellular carcinoma (HCC) compared to sorafenib. However, the significantly higher costs of toripalimab and bevacizumab raise concerns about the cost-effectiveness of TOR-BEV.
Open in Who Shared Issue with article?
See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Chuangao

Contact Chuangao, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified